A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis

Abstracts/Posters/Presentations:

• D. Matei, R. Ramasubbaiah, J. Schilder, S. M. Perkins, C. Whalen, T. Breen, C. S. Johnson, M. Callahan, T. Jones, G. Sutton. A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: Hoosier Oncology Group GYN06-111. Accepted to the scientific program in the general poster session at the ASCO Annual Meeting June 4-8, 2010, Chicago, IL. J Clin Oncol 28:15s, 2010 (suppl; abstr 5108)

Manuscripts/Articles:

• R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, M. Callahan, T. Jones, G. Sutton, D. Matei. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group: GYN06-111. Gynecologic Oncology (2011). DOI:10.1016/j.ygyno.2011.08.033. See abstract.